Primary completion· ClinicalTrials.gov
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intr
SurVaxM History and Updates
12 events · 2019 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
0
FDA Approvals
0
Label Revisions
12
Trial Milestones
0
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-03Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for SurVaxM since 2019, drawn from openFDA, ClinicalTrials.gov, and PubMed.
Upcoming & expected milestones
Primary completion· ClinicalTrials.gov
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intr
Past events
2024
Results posted· ClinicalTrials.gov
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Primary completion· ClinicalTrials.gov
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
2022
Trial started· ClinicalTrials.gov
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intr
2021
Trial registered· ClinicalTrials.gov
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Trial started· ClinicalTrials.gov
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Primary completion· ClinicalTrials.gov
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Trial registered· ClinicalTrials.gov
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intr
Trial registered· ClinicalTrials.gov
SurVaxM Expanded Access Protocol
2020
Trial started· ClinicalTrials.gov
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
2019
Trial registered· ClinicalTrials.gov
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.